Amylyx Pharmaceuticals, Inc.(NASDAQ:AMLX) 
Amylyx Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company is developing AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taur...
Website: https://amylyx.com
Founded: 2013
IPO Price: $19 (Jan 07, 2022)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 3.32
H 3.56
L 3.26
C 3.43
V 914,194
10EMA 3.43
20EMA 3.43
60EMA 3.43
120EMA 3.43
250EMA 3.43